Alpha-synuclein inhibitors are a class of investigational therapies targeting the pathological aggregation of alpha-synuclein, a protein implicated in neurodegenerative diseases like Parkinson’s disease, multiple system atrophy (MSA), and dementia with Lewy bodies (DLB). Improved technologies for small molecules, monoclonal antibodies, and gene therapies accelerate the development of alpha-synuclein inhibitors.
New York, USA, Feb. 13, 2025 (GLOBE NEWSWIRE) — Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight
Alpha-synuclein inhibitors are a class of investigational therapies targeting the pathological aggregation of alpha-synuclein, a protein implicated in neurodegenerative diseases like Parkinson’s disease, multiple system atrophy (MSA), and dementia with Lewy bodies (DLB). Improved technologies for small molecules, monoclonal antibodies, and gene therapies accelerate the development of alpha-synuclein inhibitors.
DelveInsight’s ‘
A snapshot of the Pipeline Alpha-Synuclein Inhibitors Drugs mentioned in the report:
| Drugs | Company | Phase | Indication | RoA |
| Lu AF82422 | Genmab/Lundbeck A/S | III | Multiple system atrophy | Intravenous |
| UCB 0599 | UCB Biopharma | II | Parkinson’s disease | Oral |
| ATH 434 | Prana Biotechnology | II | Multiple system atrophy | Oral |
| Exidavnemab | Bioarctic | II | Parkinson’s disease | Intravenous |
| MEDI 1341 | MedImmune/Takeda | II | Multiple system atrophy/Parkinson’s disease | Intravenous |
| Prasinezumab | Prothena Corporation/Roche | II | Parkinson’s disease | Intravenous |
| Emrusolmin | Modag | II | Multiple system atrophy; Parkinson’s disease; Unspecified | Oral |
Learn more about the emerging alpha-synuclein inhibitors @ Alpha-Synuclein Inhibitors Clinical Trials
Alpha-Synuclein Inhibitors Therapeutics Assessment
The alpha-synuclein inhibitors pipeline report proffers an integral view of the emerging alpha-synuclein inhibitors segmented by stage, product type, molecule type, and route of administration.
Scope of the Alpha-Synuclein Inhibitors Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Infusion, Intradermal, Intramuscular, Intranasal, Intravaginal, Oral, Parenteral, Subcutaneous, Topical
- Therapeutics Assessment By Molecule Type: Vaccines, Monoclonal antibody, Peptides, Polymer, Small molecule
- Key Alpha-Synuclein Inhibitors Companies: Annovis Bio, UCB Biopharma, Alterity Therapeutics, Denali Therapeutics Inc, Lundbeck A/S, AbbVie, AstraZeneca, Nitrome Biosciences, AFFiRiS, Prothena Corporation, Roche, Proclara Biosciences, Modag, ProMIS Neurosciences, and others
- Key Alpha-Synuclein Inhibitors Pipeline Therapies: Buntanetap, UCB 0599, ATH 434, ATV:aSyn, Lu AF82422, ABBV 0805, MEDI 1341, Affitope PD01, Affitope PD03, Prasinezumab, NPT 189,anle 138b, Anti-Nitrated Alpha Synuclein Antibody, PMN442 and others.
Dive deep into rich insights for new alpha-synuclein inhibitors, visit @ Alpha-Synuclein Inhibitors Drugs
Table of Contents
| 1. | Alpha-Synuclein Inhibitors Pipeline Report Introduction |
| 2. | Alpha-Synuclein Inhibitors Pipeline Report Executive Summary |
| 3. | Alpha-Synuclein Inhibitors Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Alpha-Synuclein Inhibitors Clinical Trial Therapeutics |
| 6. | Alpha-Synuclein Inhibitors Pipeline: Late-Stage Products (Pre-registration) |
| 7. | Alpha-Synuclein Inhibitors Pipeline: Late-Stage Products (Phase III) |
| 8. | Alpha-Synuclein Inhibitors Pipeline: Mid-Stage Products (Phase II) |
| 9. | Alpha-Synuclein Inhibitors Pipeline: Early-Stage Products (Phase I) |
| 10. | Alpha-Synuclein Inhibitors Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the Alpha-Synuclein Inhibitors Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the Alpha-Synuclein Inhibitors Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the alpha-synuclein inhibitors pipeline therapeutics, reach out @ Alpha-Synuclein Inhibitors Therapeutics
Related Reports
Parkinson’s Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson’s disease companies, including UCB Biopharma SRL, Novartis, Annovis Bio, Supernus Pharmaceuticals, Inc., Britannia Pharmaceutical, Pharma Two B, Mitsubishi Tanabe Pharma (NeuroDerm), AbbVie, Cerevel Therapeutics, Cerevance, among others.
Parkinson’s Disease Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Parkinson’s disease companies, including Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., among others.
Cell and Gene Therapy in Parkinson’s Disease Market
Cell and Gene Therapy in Parkinson’s Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key cell and gene therapy in Parkinson’s disease companies including MeiraGTx, Hope Biosciences, Sumitomo Pharma, Prevail Therapeutics, BlueRock Therapeutics, Voyager Therapeutics, among others.
Parkinson’s Disease Psychosis Market
Parkinson’s Disease Psychosis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson’s disease psychosis companies, including Sumitomo Pharma America Inc., Vanda Pharmaceuticals, Acadia Pharmaceuticals Inc., Otsuka America Pharmaceutical, Lundbeck LLC, Jazz Pharmaceuticals, Alkahest Inc., Sandoz, Sio Gene Therapies, Axovant Sciences Ltd, among others.
Parkinson’s Disease-Related Dementia Market
Parkinson’s Disease-Related Dementia Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Parkinson’s disease-related dementia companies, including AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., among others.
DelveInsight’s Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.
Other Business Consulting Services
Healthcare Conference Coverage
Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
CONTACT: Contact Us Shruti Thakur [email protected] +14699457679 www.delveinsight.com
The post Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight first appeared on CXP – Customer Experience Asia.
